We previously proposed that Epithelial-Mesenchymal Transition (EMT), a developmental mechanism, becomes high-jacked by carcinoma cells for their invasion and metastasis and have established an EMT scoring system applicable to all carcinoma. In this presentation, I will discuss mechanisms positioning carcinoma cells along the EMT spectrum. I will then describe our strategy to harness the EMT concept as a complementary strategy to currently available targeted therapeutics. I shall present the potential to treat mesenchymal-like tumors in bladder carcinoma. I will also show that we can potentially improve immunotherapy-based treatment by interfering with the EMT phenotype.